2022 Publications
Hassan-Zahraee M, Ye Z, Xi L, Baniecki ML, Li X, Hyde CL, Zhang J, Raha N, Karlsson F, Quan J, Ziemek D, Neelakantan S, Lepsy C, Allegretti JR, Romatowski J, Scherl EJ, Klopocka M, Danese S, Chandra DE, Schoenbeck U, Vincent MS, Longman R, Hung KE. Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis. Inflamm Bowel Dis. 2022 Mar 2;28(3):434-446. doi: 10.1093/ibd/izab193. PMID: 34427649; PMCID: PMC8889296.
Dalal RS, Gupta S, Goodrick H, Mitri J, Allegretti JR. Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders. Inflamm Bowel Dis. 2022 Jan 5;28(1):146-149. doi: 10.1093/ibd/izab156. PMID: 34245267; PMCID: PMC8730681.
2021 Publications
Allegretti JR, Canakis A, McClure E, Marcus J, Norton BA, Hamilton MJ, Winter RW, De Silva PS, Friedman S, Korzenik JR. Infliximab De-escalation in Patients With Crohn's Disease in Clinical Remission Is Safe and Well-tolerated. Inflamm Bowel Dis. 2021 Nov 15;27(12):2031-2033. doi: 10.1093/ibd/izab131. PMID: 34142700.
Danese S, Klopocka M, Scherl EJ, Romatowski J, Allegretti JR, Peeva E, Vincent MS, Schoenbeck U, Ye Z, Hassan-Zahraee M, Rath N, Li G, Neelakantan S, Banfield C, Lepsy C, Chandra DE, Hung KE. Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study. Clin Gastroenterol Hepatol. 2021 Nov;19(11):2324-2332.e6. doi: 10.1016/j.cgh.2021.06.011. Epub 2021 Jun 12. PMID: 34126262.
Mullish BH, Allegretti JR. The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection. Therap Adv Gastroenterol. 2021 May 28;14:17562848211017725. doi: 10.1177/17562848211017725. PMID: 34104212; PMCID: PMC8165815.
Allegretti JR, Kassam Z, Hurtado J, Marchesi JR, Mullish BH, Chiang A, Thompson CC, Cummings BP. Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity. Hormones (Athens). 2021 Jan 9. [Epub ahead of print]
Dalal RS, Allegretti JR. Fecal Microbiota Transplantation for Chronic Pouchitis: Promising Novel Therapeutic or Lost Cause? Inflamm Bowel Dis. 2021 Jan 27:izab002. doi: 10.1093/ibd/izab002. [Epub ahead of print]
Dalal RS, McClure E, Marcus J, Winter RW, Hamilton MJ, Allegretti JR. COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 Feb 4:S1542-3565(21)00105-1. doi: 10.1016/j.cgh.2021.02.004. Epub ahead of print
Winter RW, Ananthakrishnan A, Burke KE, Kochar B, Chan WW, Allegretti JR. Time to Negative SARS-CoV-2 PCR Should Not Delay Care Among Patients With Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2021 Mar 15;27(4):590-592.
Dalal RS, Allegretti JR. Ustekinumab Dose Optimization in Crohn Disease: One Size Does Not Fit All. Inflamm Bowel Dis. 2021 May 17;27(6):e70.
Ianiro G, Mullish BH, Hvas CL, Segal JP, Kuijper EJ, Costello SP, Kelly CR, Allegretti JR, Fischer M, Iqbal TH, Satokari R, Kao D, van Prehn J, Ng SC, Bibbò S, Baunwall SMD, Quraishi MN, Sokol H, Zhang F, Keller J, Masucci L, Quaranta G, Kassam Z, Sanguinetti M, Tilg H, Gasbarrini A, Cammarota G. SARS-CoV-2 vaccines and donor recruitment for FMT. Lancet Gastroenterol Hepatol. 2021 Apr;6(4):264-266.
Fujimoto K, Kimura Y, Allegretti JR, Yamamoto M, Zhang YZ, Katayama K, Tremmel G, Kawaguchi Y, Shimohigoshi M, Hayashi T, Uematsu M, Yamaguchi K, Furukawa Y, Akiyama Y, Yamaguchi R, Crowe SE, Ernst PB, Miyano S, Kiyono H, Imoto S, Uematsu S. Functional Restoration of Bacteriomes and Viromes by Fecal Microbiota Transplantation. Gastroenterology. 2021 May;160(6):2089-2102.e12.
Gupta S, Mullish BH, Allegretti JR. Fecal Microbiota Transplantation: The Evolving Risk Landscape. Am J Gastroenterol. 2021 Feb 5. doi: 10.14309/ajg.0000000000001075. Epub ahead of print.
Dalal RS, Allegretti JR. Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease. Curr Opin Gastroenterol. 2021 Mar 3. doi: 10.1097/MOG.0000000000000739. Epub ahead of print.
Gupta S, Zhu J, McCarty TR, Pruce J, Kassam Z, Kelly C, Fischer M, Allegretti JR. Cost-effectiveness analysis of sequential fecal microbiota transplantation for fulminant Clostridioides difficile infection. J Gastroenterol Hepatol. 2021 Mar 7. doi: 10.1111/jgh.15483. Epub ahead of print.
Dalal RS, Esckilsen S, Barnes EL, Pruce JC, Marcus J, Allegretti JR. Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2021 Mar 26:S1542-3565(21)00338-4. doi: 10.1016/j.cgh.2021.03.028. Epub ahead of print.
Dalal RS, Mitri J, Goodrick H, Allegretti JR. Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis. Inflamm Bowel Dis. 2021 May 14:izab097. doi: 10.1093/ibd/izab097. Epub ahead of print.
Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Long MD, Stollman NH. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol. 2021 May 18. doi: 10.14309/ajg.0000000000001278. Epub ahead of print.
Allegretti JR, Nije C, McClure E, Redd WD, Wong D, Zhou JC, Bazarbashi AN, McCarty TR, Hathorn KE, Shen L, Jajoo K, Chan WW. Prevalence and impact of Clostridioides difficile infection among hospitalized patients with coranavirus disease 2019. JGH Open. 2021 Mar 30;5(5):622-625.
2020 Publications
Allegretti JR, McClure, E, Marcus J, Norton BA, Hamilton M, Winter R, Friedman S, Korzenik J. Infliximab De-escalation in Patients with Crohn’s Disease in Clinical Remission is Safe and Well Tolerated. Poster presented at DDW 2020, Chicago, IL. Abstract # 3342460
Allegretti JR, Kassam Z, Hurtado J, Carrellas M, Marchesi JR, Mullish BH, Chiang A, Cummings BP, and Thompson CC. Impact of Fecal Microbiota Transplantation on the Prevention of Metabolic Syndrome Among Patients with Obesity. Poster presented at DDW 2020, Chicago, IL. Abstract # 3342460
Mendolia G, Kassam Z, McClure E, Bi S, Chu N, Alm E, Gerardin Y, Silverstein M, Smith M, and Allegretti JR. Anaerobic Fecal Microbiota Transplantation Preparations are note Necessary for Treatment Successful Engraftment Microbial in Recurrent C.difficile Infection. Poster presented at DDW 2020, Chicago, IL. Abstract # 3342478
Allegretti JA, Njie C, McClure E, Redd WD, Wong D, Zhou JC, Bazarbashi AN, McCarty TR, Hathorn KE, Shen L, Jajoo K, Chan WW. Clostridioides difficile Infection in COVID-19 Patients. Poster presented at ACG 2020, Virtual. Abstract # S0164
Njie C, Dalal RS, Allegretti JR. Factors Associated With Ustekinumab Dose Escalation in Patients With Crohn's Disease. Poster Presented at ACG 2020, Virtual. Abstract # S0733
Dalal RS, Njie C, Gupta S, Allegretti JR. Ustekinumab Dose Intensification in Patients With Crohn’s Disease: Comparing Every 4 and Every 6-Week Dosing. Poster Presented at ACG 2020, Virtual. Abstract #S0807
Dalal RS, Gupta S, Allegretti JR. Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders. Poster presentation at AIBD 2020, Virtual. Abstract # P028.
2019 Publications
Kassam Z, Dubois N, Ramakrishna B, Ling K, Qazi T, Smith M, Kelly CR, Fischer M, Allegretti JR, Budree S, Panchal P, Kelly CP, Osman M. Donor Screening for Fecal Microbiota Transplantation. N Engl J Med. 2019;381(21):2070-2072.
Santiago M, Eysenbach L, Allegretti J, Aroniadis O, Brandt LJ, Fischer M, Grinspan A, Kelly C, Morrow C, Rodriguez M, Osman M, Kassam Z, Smith MB, Timberlake S. Microbiome predictors of dysbiosis and VRE decolonization in patients with recurrent C. difficile infections in a multi-center retrospective study. AIMS Microbiol. 2019;5(1):1-18.
Allegretti JR, Kassam Z, Fischer M, Kelly C, Chan WW. Risk Factors for Gastrointestinal Symptoms Following Successful Eradication of Clostridium difficile by Fecal Microbiota Transplantation (FMT). J Clin Gastroenterol. 2019;53(9):e405-e408.
Mullish BH, McDonald JAK, Pechlivanis A, Allegretti JR, Kao D, Barker GF, Kapila D, Petrof EO, Joyce SA, Gahan CGM, Glegola-Madejska I, Williams HRT, Holmes E, Clarke TB, Thursz MR, Marchesi JR. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection. Gut. 2019;68(10):1791-1800.
Allegretti JR, Kassam Z, Carrellas M, Mullish BH, Marchesi JR, Pechlivanis A, Smith M, Gerardin Y, Timberlake S, Pratt DS, Korzenik JR. Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial. Am J Gastroenterol. 2019;114(7):1071-1079
Allegretti JR, Kao D, Phelps E, Roach B, Smith J, Ganapini VC, Kassam Z, Xu H, Fischer M. Risk of Clostridium difficile Infection with Systemic Antimicrobial Therapy Following Successful Fecal Microbiota Transplant: Should We Recommend Anti-Clostridium difficile Antibiotic Prophylaxis? Dig Dis Sci. 2019;64(6):1668-1671
Allegretti JR, Fischer M, Sagi SV, Bohm ME, Fadda HM, Ranmal SR, Budree S, Basit AW, Glettig DL, de la Serna EL, Gentile A, Gerardin Y, Timberlake S, Sadovsky R, Smith M, Kassam Z. Fecal Microbiota Transplantation Capsules with Targeted Colonic Versus Gastric Delivery in Recurrent Clostridium difficile Infection: A Comparative Cohort Analysis of High and Low Dose. Dig Dis Sci. 2019;64(6):1672-1678. Erratum in: Dig Dis Sci. 2019 ;64(7):2059 [corrected error in title]
Cheng YW, Phelps E, Ganapini V, Khan N, Ouyang F, Xu H, Khanna S, Tariq R, Friedman-Moraco RJ, Woodworth MH, Dhere T, Kraft CS, Kao D, Smith J, Le L, El-Nachef N, Kaur N, Kowsika S, Ehrlich A, Smith M, Safdar N, Ann Misch E, Allegretti JR, Flynn A, Kassam Z, Sharfuddin A, Vuppalanchi R, Fischer M. Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience. Am J Transplant. 2019;19(2):501-511
2018 Publications
Kearney SM, Gibbons SM, Poyet M, Gurry T, Bullock K, Allegretti JR, Clish CB, Alm EJ. Endospores and other lysis-resistant bacteria comprise a widely shared core community within the human microbiota. ISME J. 2018;12(10):2403-2416.
Merker AM, Riaz M, Friedman S, Allegretti JR, Korzenik J. Legalization of Medicinal Marijuana Has Minimal Impact on Use Patterns in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018;24(11):2309-2314
Smillie CS, Sauk J, Gevers D, Friedman J, Sung J, Youngster I, Hohmann EL, Staley C, Khoruts A, Sadowsky MJ, Allegretti JR, Smith MB, Xavier RJ, Alm EJ. Strain Tracking Reveals the Determinants of Bacterial Engraftment in the Human Gut Following Fecal Microbiota Transplantation. Cell Host Microbe. 2018;23(2):229-240
Fischer M, Kao D, Kassam Z, Smith J, Louie T, Sipe B, Torbeck M, Xu H, Ouyang F, Mozaffarian D, Allegretti JR. Stool Donor Body Mass Index Does Not Affect Recipient Weight After a Single Fecal Microbiota Transplantation for C. difficile Infection. Clin Gastroenterol Hepatol. 2018;16(8):1351-1353.
Allegretti JR, Kassam Z, Chan WW. Small Intestinal Bacterial Overgrowth: Should Screening Be Included in the Pre-fecal Microbiota Transplantation Evaluation? Dig Dis Sci. 2018;63(1):193-197.
Allegretti JR, Allegretti AS, Phelps E, Xu H, Kassam Z, Fischer M. Asymptomatic Clostridium difficile Carriage Rate Post-Fecal Microbiota Transplant is Low: A Prospective Clinical and Stool Assessment. Clin Microbiol Infect. 2018;24(7):780.e1-780.e3
Allegretti JR, Phelps E, Allegretti A, Xu H, Fischer M, Kassam Z. Classifying Fecal Microbiota Transplantation Failure: An Observational Study Examining Timing and Characteristics of FMT Failures. Clin Gastroenterol Hepatol. 2018;16(11):1832-1833.
Allegretti JR, Kao D, Sitko J, Fischer M, Kassam Z. Early antibiotic use post-fecal microbiota transplantation increases the risk of treatment failure. Clin Infect Dis. 2018;66(1):134-135.
2017 Publications
Razik R, Osman M, Lieberman A, Allegretti JR, Kassam Z. Faecal microbiota transplantation for Clostridium difficile infection: a multicentre study of non-responders. Med J Aust. 2017;207(4):159-160.
Qazi T, Amaratunga T, Barnes EL, Fischer M, Kassam Z, Allegretti JR. The Risk of Inflammatory Bowel Disease Flares after Fecal Microbiota Transplantation: Systematic Review and Meta-Analysis. Gut Microbes. 2017;8(6):574-588.
Allegretti JR, Barnes EL, Stevens B, Storm M, Ananthkrishnan A, Yajnik V, Korzenik JR. Predictors of Clinical Response and Remission at One year among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. Dig Dis Sci. 2017;62(6):1590-1596.
2016 Publications
Vaughn BP, Vatanen T, Allegretti JR, Bai A, Xavier RJ, Korzenik JR, Gevers D, Ting A, Robson SC, Moss AC. Increased Intestinal Microbial Diversity following Fecal Microbiota Transplant for Active Crohn’s Disease. Inflamm Bowel Dis. 2016;22(9):2182-90 .
Allegretti JR, Kearney S, Li N, Bogart E, Bullock K, Gerber G, Bry L, Clish C, Alm E, Korzenik JR. Recurrent Clostridium difficile Infection Associates with Distinct Bile Acid and Microbiome Profiles. Aliment Pharmacol Ther. 2016;43(11):1142-53.
Fischer M, Kao D, Kelly C, Kuchipudi A, Syed-Mohammed J, Blumenkehl M, Rex D, Mellow M, Kaur M, Soko H, Cook G, Hamilton MJ, Phelps E, Sipe B, Xu H, Allegretti JR. Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22(10):2402-9.
Barnes EL, Allegretti JR. Are Anti-Tumor Necrosis Factor Trough Levels Predictive of Mucosal Healing in Patients With Inflammatory Bowel Disease?: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2016;50(9):733-41.
2015 Publications
Allegretti JR, Borges L, Lucci M, Chang M, Cao B, Collins E, Vogel B, Arthur E, Emmons D, Korzenik JR. Risk factors for Re hospitalization within 90 days in patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21(11):2583-9
Shelton E*, Allegretti JR*, Stevens B, Lucci M, Khalili H, Nguyen DD, Sauk J, Giallourakis MD, Garber MD, Hamilton MJ, Tomczak M, Makrauer FL, Burakoff RB, Levine J, de Silva P, Friedman S, Ananthakrishnan A, Korzenik JR, Yajnik V. Efficacy of vedolizumab as induction therapy in refractory IBD patients: A multicenter cohort. Inflamm Bowel Dis. 2015; 21(12):2879-85.
Allegretti JR, Barnes EL, Cameron A. Are patients with Inflammatory Bowel Disease on Chronic Immunosuppressive Therapy at increased risk of cervical high-grade dysplasia/cancer? A Meta-Analysis. Inflamm Bowel Dis. 2015;21(5):1089-97.
Ravikoff Allegretti J, Courtwright A, Lucci M, Korzenik JR, Levine J. Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(13):2809-14.